Heart failure: understanding the condition and navigating its management

Heart failure (HF) is a progressive clinical syndrome that affects millions of people worldwide and significantly contributes to morbidity and mortality. The condition presents as inadequate blood supply to comply with the body’s oxygen requirements because of inefficient heart function. Underlying comorbidities such as hypertension, diabetes, and structural heart disease can cause progressive heart failure. HF can be divided into three primary categories: heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF). Each type presents unique challenges regarding diagnosis and treatment, necessitating tailored clinical strategies. Pharmacological therapies such as ACE-inhibitors, beta-blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors are essential in the management of heart failure. Non-pharmacological interventions like lifestyle modifications, smoking cessation and dietary management are important. The significance of a multidisciplinary approach, particularly in enhancing long-term outcomes and quality of life in the management of HF are important. Effective management of heart fHF requires a balance between adherence to clinical guidelines and the provision of individualised care. By integrating evidence-based medicine with comprehensive patient support, healthcare providers can more effectively address the complexities of HF, enabling patients to manage their condition with increased confidence and dignity. This article examines the fundamental aspects of HF, including its pathophysiology, classification, and symptoms, while underscoring the critical need for early diagnosis and patient-centred care, through a multidisciplinary approach.